Evommune Reveals Top-Line Results From EVO756 Phase 2b Trial In Moderate-To-Severe Atopic Dermatitis; Says Trial Did Not Meet The Primary Endpoint Of Percent Change In Eczema Area And Severity Index Score From Baseline At Week 12; EVO756 Was Generally Well Tolerated; To Continue Phase 2b Development Of EVO756 In Migraine Prophylaxis; Will Not Advance EVO756 In Atopic Dermatitis

Trial did not meet the primary endpoint of percent change in Eczema Area and Severity Index (EASI) score from baseline at Week 12; EVO756 was generally well tolerated

- EVO301, the Company’s IL-18BP fusion protein, advances as lead atopic dermatitis program following positive Phase 2a proof-of-concept data

- Evommune to continue Phase 2b development of EVO756 in migraine prophylaxis

Evommune, Inc. (NYSE:EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line results from its randomized, double-blind, placebo controlled dose-ranging Phase 2b trial evaluating the efficacy and safety of oral Mas-related G-protein coupled receptor X2 (MRGPRX2) antagonist, EVO756, in adults with moderate-to-severe atopic dermatitis (AD).

The Phase 2b trial enrolled 121 adults with moderate-to-severe AD over a 12-week treatment period, with follow-up through Week 14, and did not meet the primary and secondary endpoints in any of the doses studied. Based on these results, the Company does not plan to advance EVO756 in AD.